{"id":23289,"date":"2021-04-08T11:41:00","date_gmt":"2021-04-08T09:41:00","guid":{"rendered":"https:\/\/www.maiwald.eu\/presseberichte\/dicerna-to-receive-180-million-upfront-and-up-to-60-million-in-potential-additional-milestone-paym\/"},"modified":"2022-10-12T13:39:54","modified_gmt":"2022-10-12T11:39:54","slug":"dicerna-to-receive-180-million-upfront-and-up-to-60-million-in-potential-additional-milestone-paym","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/cn\/presseberichte\/dicerna-to-receive-180-million-upfront-and-up-to-60-million-in-potential-additional-milestone-paym\/","title":{"rendered":"Dicerna to Receive $180 Million Upfront and up to $60 Million in Potential Additional Milestone Payments (Royalty Pharma)"},"content":{"rendered":"\n<p>Royalty Pharma plc (Nasdaq: RPRX) (\u201cRoyalty Pharma\u201d) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (\u201cDicerna\u201d) today announced that Royalty Pharma has acquired Dicerna\u2019s royalty interest in OXLUMO\u2122 (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. OXLUMO, which has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of primary hyperoxaluria (PH) type 1, is marketed by Alnylam Pharmaceuticals, Inc. (\u201cAlnylam\u201d).<\/p>\n\n\n\n<p>[\u2026]<\/p>\n\n\n\n<p>Gibson Dunn, Jones Day and Maiwald acted as legal advisors to Royalty Pharma. J. Wood Capital Advisors acted as Dicerna\u2019s sole financial advisor and Latham &amp; Watkins acted as legal advisor to Dicerna on the transaction.<\/p>\n\n\n\n<p>This text is a press release from Royalty Pharma. The full text version of the article can be found here:&nbsp;&nbsp;<a href=\"https:\/\/www.royaltypharma.com\/news-releases\/news-release-details\/royalty-pharma-acquires-oxlumotm-royalty-interest-dicerna-240\" target=\"_blank\" rel=\"noreferrer noopener\">Royalty Pharma Acquires Oxlumo\u2122 Royalty Interest from Dicerna for Up to $240 Million<\/a><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-23289","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/23289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":1,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/23289\/revisions"}],"predecessor-version":[{"id":23290,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/23289\/revisions\/23290"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/media?parent=23289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}